FINWIRES · TerminalLIVE
FINWIRES

$VKTX

7 stories mentioning VKTXUpdated 9d ago

Every FINWIRES story that references VKTX, newest first.

Wire

Viking Therapeutics' VK2735 Drives Substantial Optionality, Oppenheimer Says

Viking Therapeutics (VKTX) could unlock substantial additional opportunities for VK2735 through less frequent injections, oral maintenance therapy, switching patients from other weight-loss drugs and combination treatments, Oppenheimer said.Upcoming data in Q3 and 2027 could show whether VK2735 can support less frequent injectable dosing and oral dosing in a maintenance setting, the investment firm said in a Sunday note.Oppenheimer said patients taking semaglutide or tirzepatide could potentially switch to VK2735 with limited side effects if physicians use appropriate starting doses and timing, adding that its maintenance approach could support long-term treatment through steadier drug exposure and improved tolerability.Incorrect starting doses and poorly timed breaks between treatments remain the main risks when switching patients to VK2735, the note added.Oppenheimer has an outperform rating and a $100 price target on Viking Therapeutics, adding that an oral combination of VK2735 and VK3019 could target weight loss through three complementary pathways in a single pill.Shares of Viking Therapeutics were up 2.3% in Monday trading.Price: $32.47, Change: $+0.73, Percent Change: +2.30%

$VKTX
Wire

Viking's Obesity Treatments Advance as New Data, Trials Loom, Oppenheimer Says

Viking Therapeutics' (VKTX) obesity drug programs continue to move forward, with new study results expected this quarter, a Phase 3 trial for its oral drug planned for later this year, and another candidate beginning clinical testing, Oppenheimer said Wednesday in a report.Viking is focusing its lead drug, VK2735, on helping patients keep weight off over time, not just on hitting the highest possible weight-loss number, and the company is building its approach around long-term use and patient choice, Oppenheimer said.Viking is developing both injectable and oral versions of VK2735, which may give patients more flexibility, the report said. Oppenheimer highlighted VK2809 as a potential treatment for nonalcoholic steatohepatitis, a liver disease, that may attract partnership interest.Oppenheimer rates Viking stock as outperform with a $100 price target.Price: $32.13, Change: $-1.30, Percent Change: -3.89%

$VKTX
Insider Trading

Viking Therapeutics Insider Sold Shares Worth $609,636, According to a Recent SEC Filing

Marianna Mancini, Chief Operating Officer, on July 28, 2026, sold 18,217 shares in Viking Therapeutics (VKTX) for $609,636. Following the Form 4 filing with the SEC, Mancini has control over a total of 422,760 common shares of the company, with 422,760 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1607678/000119312526324446/xslF345X05/ownership.xml

$VKTX
Insider Trading

Viking Therapeutics Insider Sold Shares Worth $710,141, According to a Recent SEC Filing

Greg Zante, Chief Financial Officer, on July 28, 2026, sold 21,217 shares in Viking Therapeutics (VKTX) for $710,141. Following the Form 4 filing with the SEC, Zante has control over a total of 212,204 common shares of the company, with 212,204 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1607678/000119312526324447/xslF345X05/ownership.xml

$VKTX
Insider Trading

Viking Therapeutics Insider Sold Shares Worth $4,947,888, According to a Recent SEC Filing

Brian Lian, Director, President and Chief Executive Officer, on July 28, 2026, sold 148,517 shares in Viking Therapeutics (VKTX) for $4,947,888. Following the Form 4 filing with the SEC, Lian has control over a total of 2,572,441 common shares of the company, with 2,572,441 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1607678/000119312526324448/xslF345X05/ownership.xml

$VKTX
Research

Lake Street Initiates Viking Therapeutics With Buy Rating, $89 Price Target

Viking Therapeutics (VKTX) has an average rating of Buy and mean price target of $94.62, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$VKTX
Wire

Viking Therapeutics Q1 Viewed as Supporting Maintenance Profile, Oppenheimer Says

Viking Therapeutics (VKTX) increased focus on maintenance dosing in its obesity program, with additional maintenance arms expected to further refine long-term dosing of VK2735, Oppenheimer said.The company added four additional subcutaneous maintenance arms, bringing the total to eight, which are expected to inform dosing decisions for its Vanquish extension studies and ongoing maintenance evaluation.Oppenheimer said in a Wednesday note that it expects data from the subcutaneous maintenance program in 3Q26, with flat weight loss outcomes viewed as a positive result. The brokerage said the company's approach to maintenance is differentiated from competitors and aligned with its healthy aging thesis.The investment firm also said insights from new CCO Neil Aubuchon are helping refine VK2735's development strategy and overall product positioning.Oppenheimer has an outperform rating on the stock with a price target of $100.Shares of Viking were down 4.1% in Thursday trading.Price: $30.02, Change: $-1.31, Percent Change: -4.18%

$VKTX

Track with the FINWIRES app suite

FolioX
FolioX
Track VKTX in your portfolio
WheelAI
WheelAI
Analyze VKTX options with the wheel strategy
StockInsider
StockInsider
See market sentiment on VKTX